PE20060159A1 - Monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-{[(1r)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2-(1h)-quinolinona en forma cristalina y el proceso para su preparacion - Google Patents
Monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-{[(1r)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2-(1h)-quinolinona en forma cristalina y el proceso para su preparacionInfo
- Publication number
- PE20060159A1 PE20060159A1 PE2005000338A PE2005000338A PE20060159A1 PE 20060159 A1 PE20060159 A1 PE 20060159A1 PE 2005000338 A PE2005000338 A PE 2005000338A PE 2005000338 A PE2005000338 A PE 2005000338A PE 20060159 A1 PE20060159 A1 PE 20060159A1
- Authority
- PE
- Peru
- Prior art keywords
- hydroxy
- compound
- preparation
- metoxyphenyl
- quinolinone
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE AL MONOCLORHIDRATO DE 8-HIDROXI-5-[(1R)-1-HIDROXI-2-{[(1R)-2-(4-METOXIFENIL)-1-METILETIL]AMINO}ETIL]-2-(1H)-QUINOLINONA DE FORMULA (I), EN FORMA CRISTALINA, CARACTERIZADO POR PRESENTAR UN RANGO DE FUSION DE 180 A 200 °C DETEMINADO POR CALORIMETRIA DIFERENCIAL DE BARRIDO, Y MEDIANTE UN PATRON DE DIFRACCION DE RAYOS X QUE TIENE ENTRE OTROS, UNO O MAS DE LOS SIGUIENTES PICOS CARACTERISTICOS: 12,2; 13,6; 16,3; 18,0; 21,9; 22,8; 23,5; 24,9; 26,6; 27,6; 28,529,4; 29,9; 33,9 * 0,2 GRADOS/2*, ADEMAS TIENE UN GRADO DE CRISTALINIDAD DE AL MENOS 90% EXPRESADO COMO PORCENTAJE DEL PESO CRISTALINO CON RESPECTO AL PESO TOTAL DEL COMPUESTO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION QUE COMPRENDE EN CRISTALIZAR O RECRISTALIZAR EL COMPUESTO DESDE UNA SOLUCION ACUOSA DE ETANOL, AGREGAR DIISOPROPIL ETER DONDE LA SOLUCION ACUOSA DE ETANOL SE CONCENTRA HASTA UN VOLUMEN COMPRENDIDO ENTRE 1/2 Y 1/3 DEL VOLUMEN INICIAL, Y DONDE LA ADICION DEL DIISOPROPIL ETER SE LLEVA A CABO DURANTE AL MENOS 5 MINUTOS. ESTE COMPUESTO ES BRONCODILATADOR YA QUE ES UN ESTIMULANTE DEL RECEPTOR ß ADRENERGICO Y SE UTILIZA EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS PARA INHALACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04007045 | 2004-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060159A1 true PE20060159A1 (es) | 2006-04-04 |
Family
ID=34963779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000338A PE20060159A1 (es) | 2004-03-24 | 2005-03-23 | Monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-{[(1r)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2-(1h)-quinolinona en forma cristalina y el proceso para su preparacion |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20070197586A1 (es) |
| EP (1) | EP1729773B1 (es) |
| JP (1) | JP2007530489A (es) |
| KR (1) | KR20070001946A (es) |
| CN (2) | CN1929840B (es) |
| AR (1) | AR048339A1 (es) |
| AT (1) | ATE399552T1 (es) |
| AU (1) | AU2005224032A1 (es) |
| BR (1) | BRPI0508213A (es) |
| CA (1) | CA2560650A1 (es) |
| CY (1) | CY1108323T1 (es) |
| DE (1) | DE602005007871D1 (es) |
| DK (1) | DK1729773T3 (es) |
| EA (1) | EA010128B1 (es) |
| ES (1) | ES2309739T3 (es) |
| HR (1) | HRP20080495T3 (es) |
| IL (1) | IL178227A0 (es) |
| MA (1) | MA28549B1 (es) |
| MX (1) | MXPA06010515A (es) |
| NO (1) | NO20064274L (es) |
| NZ (1) | NZ550010A (es) |
| PE (1) | PE20060159A1 (es) |
| PL (1) | PL1729773T3 (es) |
| PT (1) | PT1729773E (es) |
| RS (1) | RS50602B (es) |
| SI (1) | SI1729773T1 (es) |
| TN (1) | TNSN06249A1 (es) |
| UA (1) | UA86221C2 (es) |
| WO (1) | WO2005089760A1 (es) |
| ZA (1) | ZA200607907B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1953143A1 (en) * | 2007-01-30 | 2008-08-06 | CHIESI FARMACEUTICI S.p.A. | Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
| EP2116537A1 (en) | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
| EP2116536A1 (en) | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride |
| WO2011015289A1 (en) | 2009-08-04 | 2011-02-10 | Chiesi Farmaceutici S.P.A. | 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate |
| EP2360147A1 (en) | 2010-02-22 | 2011-08-24 | CHIESI FARMACEUTICI S.p.A. | Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| GB9603237D0 (en) * | 1996-02-16 | 1996-04-17 | Sandoz Ltd | Organic compounds |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| CA2534693A1 (en) * | 2003-08-05 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising steroids and a betamimetic |
| EP1953143A1 (en) * | 2007-01-30 | 2008-08-06 | CHIESI FARMACEUTICI S.p.A. | Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
| EP2116537A1 (en) * | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride |
| EP2116536A1 (en) * | 2008-05-07 | 2009-11-11 | CHIESI FARMACEUTICI S.p.A. | Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride |
-
2005
- 2005-03-23 AR ARP050101185A patent/AR048339A1/es not_active Application Discontinuation
- 2005-03-23 PE PE2005000338A patent/PE20060159A1/es not_active Application Discontinuation
- 2005-03-24 DE DE602005007871T patent/DE602005007871D1/de active Active
- 2005-03-24 UA UAA200609448A patent/UA86221C2/uk unknown
- 2005-03-24 DK DK05730069T patent/DK1729773T3/da active
- 2005-03-24 ES ES05730069T patent/ES2309739T3/es active Active
- 2005-03-24 EP EP05730069A patent/EP1729773B1/en active Active
- 2005-03-24 CN CN2005800076387A patent/CN1929840B/zh not_active Expired - Fee Related
- 2005-03-24 WO PCT/EP2005/003144 patent/WO2005089760A1/en active Application Filing
- 2005-03-24 KR KR1020067015966A patent/KR20070001946A/ko not_active Application Discontinuation
- 2005-03-24 JP JP2007504359A patent/JP2007530489A/ja not_active Withdrawn
- 2005-03-24 CA CA002560650A patent/CA2560650A1/en not_active Abandoned
- 2005-03-24 NZ NZ550010A patent/NZ550010A/en unknown
- 2005-03-24 CN CN200910173473A patent/CN101812017A/zh active Pending
- 2005-03-24 EA EA200601531A patent/EA010128B1/ru not_active IP Right Cessation
- 2005-03-24 US US10/593,571 patent/US20070197586A1/en not_active Abandoned
- 2005-03-24 MX MXPA06010515A patent/MXPA06010515A/es active IP Right Grant
- 2005-03-24 AU AU2005224032A patent/AU2005224032A1/en not_active Abandoned
- 2005-03-24 PL PL05730069T patent/PL1729773T3/pl unknown
- 2005-03-24 RS RSP-2008/0393A patent/RS50602B/sr unknown
- 2005-03-24 AT AT05730069T patent/ATE399552T1/de not_active IP Right Cessation
- 2005-03-24 SI SI200530320T patent/SI1729773T1/sl unknown
- 2005-03-24 PT PT05730069T patent/PT1729773E/pt unknown
- 2005-03-24 BR BRPI0508213-7A patent/BRPI0508213A/pt not_active IP Right Cessation
-
2006
- 2006-08-04 TN TNP2006000249A patent/TNSN06249A1/en unknown
- 2006-09-21 ZA ZA2006/07907A patent/ZA200607907B/en unknown
- 2006-09-21 IL IL178227A patent/IL178227A0/en not_active IP Right Cessation
- 2006-09-21 NO NO20064274A patent/NO20064274L/no not_active Application Discontinuation
- 2006-10-23 MA MA29409A patent/MA28549B1/fr unknown
-
2008
- 2008-09-04 CY CY20081100962T patent/CY1108323T1/el unknown
- 2008-10-01 HR HR20080495T patent/HRP20080495T3/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070197586A1 (en) | 2007-08-23 |
| WO2005089760A1 (en) | 2005-09-29 |
| EP1729773A1 (en) | 2006-12-13 |
| NZ550010A (en) | 2010-08-27 |
| CN1929840B (zh) | 2010-12-08 |
| ZA200607907B (en) | 2008-04-30 |
| EA200601531A1 (ru) | 2007-04-27 |
| BRPI0508213A (pt) | 2007-07-17 |
| HRP20080495T3 (en) | 2008-11-30 |
| AR048339A1 (es) | 2006-04-19 |
| MXPA06010515A (es) | 2007-03-30 |
| EA010128B1 (ru) | 2008-06-30 |
| CN101812017A (zh) | 2010-08-25 |
| NO20064274L (no) | 2006-10-13 |
| DK1729773T3 (da) | 2008-10-20 |
| PL1729773T3 (pl) | 2008-12-31 |
| KR20070001946A (ko) | 2007-01-04 |
| UA86221C2 (en) | 2009-04-10 |
| CA2560650A1 (en) | 2005-09-29 |
| CY1108323T1 (el) | 2014-02-12 |
| TNSN06249A1 (en) | 2007-12-03 |
| MA28549B1 (fr) | 2007-04-03 |
| PT1729773E (pt) | 2008-09-29 |
| IL178227A0 (en) | 2006-12-31 |
| EP1729773B1 (en) | 2008-07-02 |
| SI1729773T1 (sl) | 2008-10-31 |
| CN1929840A (zh) | 2007-03-14 |
| DE602005007871D1 (de) | 2008-08-14 |
| ATE399552T1 (de) | 2008-07-15 |
| ES2309739T3 (es) | 2008-12-16 |
| AU2005224032A1 (en) | 2005-09-29 |
| RS50602B (sr) | 2010-05-07 |
| JP2007530489A (ja) | 2007-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120619A1 (es) | FORMULACION FARMACEUTICA ESTABLE DE N-[2-(2,1,3-BENZOTIADIAZOL-5-ILAMINO)-6-(2,6-DICLOROFENIL)PIRIDO[2,3-d]PIRIMIDIN-7-IL]-N'-(1,1-DIMETILETIL)UREA | |
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| PE20060159A1 (es) | Monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-{[(1r)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2-(1h)-quinolinona en forma cristalina y el proceso para su preparacion | |
| AR073073A1 (es) | Compuestos de pirrolo [ 2,3-d] pirimidina. | |
| CL2008002794A1 (es) | Compuestos derivados de dihidropirimidina-2,4-(1h,3h)-diona; formas cristalinas, compuestos intermediarios; procedimiento de preparación de los compuestos intermediarios, composición farmacéutica; y su uso util para tratar hepatitis c en un mamífero. | |
| AR098829A1 (es) | Composiciones acuosas diluidas de saflufenacilo | |
| PE20061142A1 (es) | Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen | |
| PE20130402A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| PE20080186A1 (es) | Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2 | |
| PE20100267A1 (es) | Procedimiento para la preparacion de compuestos de aminocrotonilo | |
| ECSP099565A (es) | Compuesto de 2-amino pirimidina | |
| HRP20110807T1 (hr) | Supstituirani pirimidodiazepini korisni kao plk1 inhibitori | |
| CO6612227A2 (es) | Formulaciones concentradas acuosas que contienen saflufenacilo y glifosato | |
| HN2005000484A (es) | Nuevas composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos | |
| PE20070415A1 (es) | PROCEDIMIENTO DE PREPARACION PARA {6-[4-(4-ETIL-PIPERAZIN-1-ILMETIL)-FENIL]-7H-PIRROLO-[2,3-d]-PIRIMIDIN-4-IL]-((R)-1-FENIL-ETIL)-AMINA | |
| RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
| CO6410293A2 (es) | Nueva formula cristalina vi de la agomelatina preparación y uso de la misma | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| UY28253A1 (es) | Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparación, medicamentos que comprenden este compuesto y su uso. | |
| RU2011108663A (ru) | Способы получения метилового эфира 4-оксооктагидроиндол-1-карбоновой кислоты и ее производные | |
| AR069325A1 (es) | Proceso para preparar sales de dibenzoil - l - tartrato | |
| PE20121052A1 (es) | Composicion de sal no apelmazante y procedimiento de preparacion de la misma | |
| BRPI0607811A2 (pt) | derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmo, processo para preparar a referida composição e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |